This article is more than 5 years old. Information may no longer be current.
Atlantic Health System Cancer Care appoints chief of hematology, oncology
Click Here to Manage Email Alerts
Atlantic Health System Cancer Care has named Missak Haigentz, MD, as chief of hematology and oncology at Morristown Medical Center.
Haigentz also will serve as medical director of Atlantic Hematology and Oncology for Atlantic Medical Group at Carol G. Simon Cancer Center.
Haigentz, whose research focuses on lung cancer and head and neck cancer, has extensive expertise related to the design and implementation of clinical trials designed to improve the lives of patients with cancer.
“Dr. Haigentz is a leader in head and neck cancer research, treatment and education,” Eric Whitman, MD, medical director of Atlantic Health System Cancer Care, said in a press release. “We are proud that he has chosen to join our cancer care team. His appointment enhances Atlantic Health System’s capabilities in clinical trials for head and neck cancers, as well as for lung cancer. He also brings with him extensive experience in using the most innovative, targeted cancer treatments and immunotherapy, which we will now be able to offer to our patients.”
Haigentz previously served as director of the clinical trials office at NCI–designated Albert Einstein Cancer Center in New York. He also held the academic rank of professor of medicine (oncology) and otorhinolaryngology — head and neck surgery at Albert Einstein College of Medicine.
“Atlantic Health System is known for its strong leadership commitment to innovation, clinical research, patient-centered care, and to bringing the latest treatments to cancer patients,” Haigentz said in the release. “Therefore, as a longtime New Jersey resident, AHS Cancer Care was the natural choice for me in terms of making an impact on patients’ treatment outcomes in my community.
“As medical director of Atlantic Hematology and Oncology, my goal is to provide subspecialty-specific cancer care at an academic level, with access to clinical trials and breakthrough medications, while preserving the comfort of compassionate and individualized attention patients and families need and deserve, and to collaborate with outstanding multidisciplinary specialists in the Atlantic Health System Cancer Care team in providing the most innovative and effective therapeutic options,” Haigentz added.